WO2000017346A3 - Molecules hybridantes en epingle a cheveux servant a moduler l'expression genique - Google Patents

Molecules hybridantes en epingle a cheveux servant a moduler l'expression genique Download PDF

Info

Publication number
WO2000017346A3
WO2000017346A3 PCT/US1999/021865 US9921865W WO0017346A3 WO 2000017346 A3 WO2000017346 A3 WO 2000017346A3 US 9921865 W US9921865 W US 9921865W WO 0017346 A3 WO0017346 A3 WO 0017346A3
Authority
WO
WIPO (PCT)
Prior art keywords
hybridizer
gene expression
hairpin
molecules
modulation
Prior art date
Application number
PCT/US1999/021865
Other languages
English (en)
Other versions
WO2000017346A2 (fr
Inventor
Thomas Hartmann
Michael Zwick
James Thompson
Thale Jarvis
Original Assignee
Ribozyme Pharm Inc
Thomas Hartmann
Michael Zwick
James Thompson
Thale Jarvis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribozyme Pharm Inc, Thomas Hartmann, Michael Zwick, James Thompson, Thale Jarvis filed Critical Ribozyme Pharm Inc
Priority to EP99969438A priority Critical patent/EP1115859A2/fr
Priority to AU60552/99A priority patent/AU6055299A/en
Priority to CA002343067A priority patent/CA2343067A1/fr
Priority to JP2000574246A priority patent/JP2002526072A/ja
Publication of WO2000017346A2 publication Critical patent/WO2000017346A2/fr
Publication of WO2000017346A3 publication Critical patent/WO2000017346A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne de nouvelles molécules hybridantes en épingle à cheveux d'acides nucléiques capables de moduler l'expression génique; elles peuvent servir dans la validation de cibles, l'identification des fonctions de gènes et la thérapie de l'humain.
PCT/US1999/021865 1998-09-21 1999-09-20 Molecules hybridantes en epingle a cheveux servant a moduler l'expression genique WO2000017346A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99969438A EP1115859A2 (fr) 1998-09-21 1999-09-20 Molecules hybridantes en epingle a cheveux servant a moduler l'expression genique
AU60552/99A AU6055299A (en) 1998-09-21 1999-09-20 Hairpin hybridizer molecules for modulation of gene expression
CA002343067A CA2343067A1 (fr) 1998-09-21 1999-09-20 Molecules hybridantes en epingle a cheveux servant a moduler l'expression genique
JP2000574246A JP2002526072A (ja) 1998-09-21 1999-09-20 遺伝子発現の調節のためのヘアピンハイブリダイザー分子

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10117498P 1998-09-21 1998-09-21
US60/101,174 1998-09-21

Publications (2)

Publication Number Publication Date
WO2000017346A2 WO2000017346A2 (fr) 2000-03-30
WO2000017346A3 true WO2000017346A3 (fr) 2000-08-03

Family

ID=22283374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/021865 WO2000017346A2 (fr) 1998-09-21 1999-09-20 Molecules hybridantes en epingle a cheveux servant a moduler l'expression genique

Country Status (5)

Country Link
EP (1) EP1115859A2 (fr)
JP (1) JP2002526072A (fr)
AU (1) AU6055299A (fr)
CA (1) CA2343067A1 (fr)
WO (1) WO2000017346A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592250B2 (en) 2002-02-01 2017-03-14 Life Technologies Corporation Double-stranded oligonucleotides

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596490B2 (en) 2000-07-14 2003-07-22 Applied Gene Technologies, Inc. Nucleic acid hairpin probes and uses thereof
EP2213737B1 (fr) 2002-02-01 2012-11-07 Life Technologies Corporation Oligonucleotides double brin
MX2007008065A (es) * 2004-12-30 2008-03-04 Todd M Hauser Composiciones y metodos para modular la expresion genica usando oligonucleotidos autoprotegidos.
JP4936343B6 (ja) 2008-10-23 2018-06-27 国立大学法人 東京大学 ｍｉｃｒｏＲＮＡの機能阻害法
AU2017211461B2 (en) 2016-01-26 2023-01-12 Nissan Chemical Corporation Single-stranded oligonucleotide
US11572558B2 (en) 2017-02-06 2023-02-07 Nissan Chemical Corporation Single-stranded oligonucleotide
AU2018307294A1 (en) 2017-07-26 2020-02-20 Nissan Chemical Corporation Single-stranded oligonucleotide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019732A1 (fr) * 1991-04-25 1992-11-12 Genset Oligonucleotides fermes, antisens et sens, et leurs applications
WO1999054459A2 (fr) * 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Molecules d'acides nucleiques presentant de nouvelles compositions chimiques capables de moduler l'expression genique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019732A1 (fr) * 1991-04-25 1992-11-12 Genset Oligonucleotides fermes, antisens et sens, et leurs applications
WO1999054459A2 (fr) * 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Molecules d'acides nucleiques presentant de nouvelles compositions chimiques capables de moduler l'expression genique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANNUAL MEETING OF THE PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY 98, PART II;SAN FRANCISCO, CALIFORNIA, USA; APRIL 18-22, 1998 *
HOSONO K ET AL: "Properties and anti-HIV activating of hairpin antisense oligonucleotides containing 2'-methoxynucleosides with base-pairing in the stem region at the 3'-end.", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 7, no. 2, 1996, pages 86 - 93, XP000877270, ISSN: 0956-3202 *
LI JING ET AL: "The base-paired strand of a stable hairpin DNA can template RNase H cleavage of a RNA target site. A potential stringency clamp approach to antisense strategy.", FASEB JOURNAL, vol. 12, no. 5, 20 March 1998 (1998-03-20), pages A775, XP002131931, ISSN: 0892-6638 *
MONIA B P ET AL: "ANTITUMOR ACTIVITY OF A PHOSPHOROTHIOATE ANTISENSE OLIGODEOXYNUCLEOTIDE TARGETED AGAINST C-RAF KINASE", NATURE MEDICINE, vol. 2, no. 6, 6 June 1996 (1996-06-06), pages 668 - 675, XP002073792, ISSN: 1078-8956 *
TANG J Y ET AL: "SELF-STABILIZED ANTISENSE OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES: PROPERTIES AND ANTI-HIV ACTIVITY", NUCLEIC ACIDS RESEARCH, vol. 21, no. 11, 1993, pages 2729 - 2735, XP002030620, ISSN: 0305-1048 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592250B2 (en) 2002-02-01 2017-03-14 Life Technologies Corporation Double-stranded oligonucleotides

Also Published As

Publication number Publication date
JP2002526072A (ja) 2002-08-20
AU6055299A (en) 2000-04-10
EP1115859A2 (fr) 2001-07-18
CA2343067A1 (fr) 2000-03-30
WO2000017346A2 (fr) 2000-03-30

Similar Documents

Publication Publication Date Title
WO1999054459A8 (fr) Molecules d'acides nucleiques presentant de nouvelles compositions chimiques capables de moduler l'expression genique
AU2002258518A1 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2002036743A3 (fr) Modulation antisens de l'expression de calreticuline
WO2001019981A3 (fr) Genomique fonctionnelle utilisant des proteines a doigts de zinc
WO2003012057A3 (fr) Modulation antisens de l'expression du serum amyloide a4
WO2004005460A3 (fr) Modulation antisens de l'expression de la reductase de hmg-coa
WO2003010284A3 (fr) Modulation antisens de l'expression de la proteine reactive c
WO2002061060A3 (fr) Proteines kinases humaines isolees, molecule d'acide nucleique codant ces proteines kinases humaines et leurs utilisations
WO2003046132A3 (fr) Modulation antisens de l'expression du myd88
EP1135402A4 (fr) Modulation antisens de l'expression d'egr-1
WO2003022222A3 (fr) Modulation anti-sens de l'expression d'une proteine kinase r
WO2000017346A3 (fr) Molecules hybridantes en epingle a cheveux servant a moduler l'expression genique
EP1131332A4 (fr) Modulation antisens de l'expression de la kappa b kinase beta inhibitrice
EP1131107A4 (fr) Modulation antisens de l'expression de kappa b kinase alpha inhibitrice
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
EP1212456A4 (fr) Modulation antisens de l'expression de shp-2
WO1999002704A3 (fr) Phosphatase a double specificite et procedes d'utilisation
WO2003053341A3 (fr) Modulation antisens de l'expression de ship-1
EP1268507A4 (fr) Modulation antisens de l'expression du facteur de transcription e2f-1
WO2002095053A3 (fr) Modulation antisens de l'expression des src-c
WO2001088124A3 (fr) Procede et reactif destine a l'inhibition d'erg
WO2001031051A3 (fr) Modulation par antisens de l'expression de la proteine kinase c-theta
WO2002062818A3 (fr) Modulation antisens de l'expression de la caseine kinase 2-alpha
WO2003052062A3 (fr) Modulation antisens de l'expression de cd36l1
WO2002055725A3 (fr) Acides nucleiques, methodes et cellules transformees destinees a moduler la production de gibberelline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 60552/99

Country of ref document: AU

ENP Entry into the national phase

Ref country code: CA

Ref document number: 2343067

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/002953

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 574246

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999969438

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999969438

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2343067

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999969438

Country of ref document: EP